907 related articles for article (PubMed ID: 17692726)
1. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
4. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
5. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
6. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
Emkey RD; Ettinger M
Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
[TBL] [Abstract][Full Text] [Related]
8. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
9. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
10. Once-monthly dosing: an effective step forward.
Reid DM
Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
[TBL] [Abstract][Full Text] [Related]
11. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in bisphosphonate therapy.
Silverman SL; Maricic M
Semin Arthritis Rheum; 2007 Aug; 37(1):1-12. PubMed ID: 17303219
[TBL] [Abstract][Full Text] [Related]
13. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
Keen R; Jodar E; Iolascon G; Kruse HP; Varbanov A; Mann B; Gold DT
Curr Med Res Opin; 2006 Dec; 22(12):2375-81. PubMed ID: 17257451
[TBL] [Abstract][Full Text] [Related]
14. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Rossini M; Viapiana O; Gatti D; Adami S
Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
[TBL] [Abstract][Full Text] [Related]
15. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein S; Jeglitsch M; McCloskey E
Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
[TBL] [Abstract][Full Text] [Related]
16. Use of bisphosphonates in the management of postmenopausal osteoporosis.
Papapoulos SE
Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
[TBL] [Abstract][Full Text] [Related]
17. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
Gold DT; Alexander IM; Ettinger MP
Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
[TBL] [Abstract][Full Text] [Related]
18. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
19. Beyond daily dosing: clinical experience.
Cooper C
Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
[TBL] [Abstract][Full Text] [Related]
20. Compliance with treatment in osteoporosis patients--an ongoing problem.
Sambrook P
Aust Fam Physician; 2006 Mar; 35(3):135-7. PubMed ID: 16525527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]